Center for Infectious Diseases and Vaccinology

Sun City Center, United States

Center for Infectious Diseases and Vaccinology

Sun City Center, United States

Time filter

Source Type

Lussier D.M.,Arizona State University | Lussier D.M.,Center for Infectious Diseases and Vaccinology | O'Neill L.,Molecular Biosciences and Biotechnology | Nieves L.M.,Center for Infectious Diseases and Vaccinology | And 11 more authors.
Journal of Immunotherapy | Year: 2015

Osteosarcoma is the most common bone cancer in children and adolescents. Although 70% of patients with localized disease are cured with chemotherapy and surgical resection, patients with metastatic osteosarcoma are typically refractory to treatment. Numerous lines of evidence suggest that cytotoxic T lymphocytes (CTLs) limit the development of metastatic osteosarcoma. We have investigated the role of PD-1, an inhibitory TNFR family protein expressed on CTLs, in limiting the efficacy of immune-mediated control of metastatic osteosarcoma. We show that human metastatic, but not primary, osteosarcoma tumors express a ligand for PD-1 (PD-L1) and that tumor-infiltrating CTLs express PD-1, suggesting this pathway may limit CTLs control of metastatic osteosarcoma in patients. PD-L1 is also expressed on the K7M2 osteosarcoma tumor cell line that establishes metastases in mice, and PD-1 is expressed on tumor-infiltrating CTLs during disease progression. Blockade of PD-1/PD-L1 interactions dramatically improves the function of osteosarcomareactive CTLs in vitro and in vivo, and results in decreased tumor burden and increased survival in the K7M2 mouse model of metastatic osteosarcoma. Our results suggest that blockade of PD-1/PD-L1 interactions in patients with metastatic osteosarcoma should be pursued as a therapeutic strategy. © 2015 Wolters Kluwer Health, Inc. All rights reserved.

Loading Center for Infectious Diseases and Vaccinology collaborators
Loading Center for Infectious Diseases and Vaccinology collaborators